The HIV-testing business lodged its initial public offering prospectus with the Australian Securities and Investment Commission on Wednesday, in its bid to raise $30 million at 20¢ a share. copied from AFR
- Forums
- IPOs
- Atomo Diagnostics IPO massively oversubscribed
The HIV-testing business lodged its initial public offering...
Featured News
Featured News
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online